The GLP is committed to full transparency. Download and review our 2019 Annual Report

Bayer asks appeals court to toss ‘speculative’ $25 million glyphosate-cancer verdict

| | December 17, 2019

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Bayer AG on [Dec. 16] said it has asked a U.S. federal appeals court to throw out a $25 million judgment it was ordered to pay to a California man who blamed the company’s Roundup weed killer for his cancer.

The case on appeal before the 9th Circuit involved the claims of Edwin Hardeman, which was the third Roundup case to go to trial in a U.S. court. A jury in March ordered Monsanto to pay $80 million in damages, saying Roundup had caused the man’s non-Hodgkin’s lymphoma. The trial court judge in July reduced that verdict to $25 million.

In a filing in the U.S. Court of Appeals for the 9th Circuit dated [Dec. 13], Bayer said the verdict defied regulatory findings and sound science, adding that the “speculative case” should never have made it before a jury.

Related article:  Glyphosate-based Roundup herbicide linked to liver disease in rats? Researcher Séralini under fire again

Bayer in a statement said it stood behind the safety of Roundup and its active ingredient glyphosate and planned to vigorously defend the more than 42,700 U.S. Roundup cancer lawsuits it faces.

In its court filing, Bayer said the Hardeman appeal had the potential to shape how every subsequent Roundup case is litigated.

Read full, original article: Bayer asks U.S. appeals court to reverse $25 million Roundup verdict

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend